P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19
371 Indexcentral nervous system effects, 167
classification,165t
distribution of drugs, 167 –168
duration of action, 165 –166
elimination, 168
infected tissue, 166
kinetics, 167 –168
lipid solubility, 165
mechanisms of action, 164 , 165f
metabolism, 168
onset of action, 165 –166
pharmacological properties,169t
physiochemical characteristics, 165 –167
physiology, 163
potency, 165 –166
preparations, 164
protein binding, 165 , 167–168
sodium ion channel binding, 3
structure,172f
toxic doses, 168
vasodilator activity, 166
logarithmic function, 54 –59
logarithms, 54 –59, 84
natural, 57 –59
semilogarithmic transformation,59f
loop diuretics, 307 –308
effects, 307 –308
kinetics, 308
mechanism of action, 307
lorazepam, 272 –273
antiemetic use, 291
losartan, 261 –262
lumaricoxib, 162
lungs, surface area, 13μreceptors, 137
macrolides, 318 –319
drug interactions, 319
kinetics, 319
mechanism of action, 318
side-effects, 319
magnesium-containing antacids, 292
malabsorption syndromes, bioavailability
influence, 9
malignant hyperthermia, 182 –184
diagnosis, 182
mechanism, 182
safe drugs, 183 –184
treatment, 182
mandelic acid, 95
mannitol, 309 –310
Marsh model of TCI, 82
mathematical models, 50 –78
mean residence time (MRT), 71
volume of distribution, 72 –73medical gases, non-anaesthetic, 128 ,
134t
medicinal chemistry, 85 –98
meglitinide, 351
meloxicam, 158 –159
membrane expansion, 164
membrane lipids, 99 –100
meropenem, 317
metabolic capacity, drugs with low level, 11
metabolism of drugs, 17 –19
drug interactions, 41 –42
enzyme induction/inhibition, 19
genetic polymorphisms, 19
neonates, 23
Phase I, 17 –18
Phase II, 18 –19
metabolites, 17
metaraminol, 212
metformin, 350
methadone, 143
methaemoglobinaemia
prilocaine,173t
risk with EMLA,170t
methicillin-resistantStaphylococcus aureus
(MRSA), 311
clindamycin activity, 323
methohexitone, 102 –103, 107–108
methoxamine, 45 , 207
methoxy group, 95
methoxyflurane, 17
methyl group, 95
methylation, 18 –19
methyldopa, 265 –266
methylprednisolone, 353
metirosine, 265
metoclopramide, 40 –41, 286–287,
295 –296
effects, 287
mechanism of action, 287
uses, 286
metolazone, 305 –307
metoprolol,225t
metronidazole,328t
mexiletine, 238
mianserin, 278
Michaelis constant, 10 –11
miconazole, 332 –333
midazolam, 45 , 89, 271–272
alfentanil concurrent administration, 146
kinetics, 272
presentation, 271
propofol co-administration, 42 , 83
uses, 272
milrinone, 215 –216
mineralocorticoid receptor, 31